Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer
| Autor: | Tian-Lu Cheng, HL Tsai, SR Lin, CW Chen, Jy Wang, Yih-Huei Uen, HM Hu, CY Lu |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Pathology Organoplatinum Compounds circulating tumour cells medicine.medical_treatment Leucovorin Perineural invasion Carcinoembryonic antigen Circulating tumor cell Recurrence Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor medicine Humans Aged Aged 80 and over Chemotherapy Univariate analysis biology business.industry Surrogate endpoint Hazard ratio Odds ratio Middle Aged Neoplastic Cells Circulating Prognosis Treatment Outcome colon cancer Chemotherapy Adjuvant Colonic Neoplasms Clinical Study postoperative relapse biology.protein Female mFOLFOX Fluorouracil business |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/bjc.2012.595 |
| Popis: | Background: This study was aimed to detect post-chemotherapeutic circulating tumour cells (CTCs) in stage III colon cancer patients and identify those who were at high risk of relapse. Methods: We used human telomerase reverse transcriptase, cytokeratin-19, cytokeratin-20, and carcinoembryonic antigen (CEA) as the biomarkers to detect CTCs in 90 stage III colon cancer patients undergoing curative resection followed by mFOLFOX chemotherapy. Results: Post-chemotherapeutic relapse occurred in 30 (33.3%) patients. By univariate analysis and multivariate proportional hazards regression analysis, perineural invasion (hazard ratio (HR): 2.752; 95% confidence interval (CI): 1.026–7.381), high post-chemotherapeutic serum CEA levels (HR: 2.895; 95% CI: 1.143–7.333) and persistent presence of post-chemotherapeutic CTCs (HR: 6.273; 95% CI: 2.442–16.117) were independent predictors of post-chemotherapeutic relapse. In addition, the persistent presence of post-chemotherapeutic CTCs strongly correlated with reduced disease-free survival and overall survival. Accuracy of detecting relapse in post-chemotherapeutic stage III colon cancer patients by analysing the persistent presence of post-chemotherapeutic CTCs was higher than that by post-chemotherapeutic CEA levels (odds ratio: 50.091 vs 5.211). Conclusion: The persistent presence of post-chemotherapeutic CTCs is a potential powerful surrogate marker for determining clinical outcome in stage III colon cancer patients receiving adjuvant mFOLFOX chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|